Abstract
Recent decades have seen a progressive increase in survival after several cancers, a trend that is set to continue with rapid improvements in molecular diagnostics and novel targeted and immunologic-based therapies. Breast cancer, the most common cancer diagnosis in adult women, is among those diagnoses with the highest survival rates, further improved by a growing armory of novel therapies supporting established cytotoxic chemotherapeutic treatments. Curative-intent chemotherapy regimens for breast cancer are traditionally based on cyclophosphamide, anthracyclines, and taxanes and, now increasingly, platinums and are known to be markedly gonadotoxic with high rates of after treatment premature ovarian insufficiency.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
